Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 May 22. doi: 10.1038/s41375-018-0037-9. [Epub ahead of print]

PMID:
29789651
2.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Mar 29. doi: 10.1038/s41375-018-0116-y. [Epub ahead of print]

PMID:
29749396
3.

Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data.

Miannay B, Minvielle S, Magrangeas F, Guziolowski C.

BMC Syst Biol. 2018 Mar 21;12(Suppl 3):32. doi: 10.1186/s12918-018-0551-4.

4.

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.

Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, Bolli N.

Leukemia. 2018 Apr;32(4):1044-1048. doi: 10.1038/leu.2017.345. Epub 2017 Dec 6. No abstract available.

5.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC.

Leukemia. 2017 Dec 6. doi: 10.1038/leu.2017.344. [Epub ahead of print]

6.

Expressed fusion gene landscape and its impact in multiple myeloma.

Cleynen A, Szalat R, Kemal Samur M, Robiou du Pont S, Buisson L, Boyle E, Chretien ML, Anderson K, Minvielle S, Moreau P, Attal M, Parmigiani G, Corre J, Munshi N, Avet-Loiseau H.

Nat Commun. 2017 Dec 1;8(1):1893. doi: 10.1038/s41467-017-00638-w.

7.

Logic programming reveals alteration of key transcription factors in multiple myeloma.

Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H, Guérin-Charbonnel C, Gouraud W, Attal M, Facon T, Munshi NC, Moreau P, Campion L, Magrangeas F, Guziolowski C.

Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9.

8.

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM.

Blood. 2017 Apr 27;129(17):2429-2436. doi: 10.1182/blood-2016-09-742296. Epub 2017 Feb 17.

9.

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC.

Blood Cancer J. 2016 Sep 2;6(9):e467. doi: 10.1038/bcj.2016.72.

10.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.

J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25.

PMID:
27114594
11.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Sakissian H, Attal M, C Munshi N, Sonneveld P, Dumontet C, Moreau P, van Duin M, Campion L, Minvielle S.

Clin Cancer Res. 2016 Sep 1;22(17):4350-4355. doi: 10.1158/1078-0432.CCR-15-3163. Epub 2016 Apr 8.

12.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H.

Blood. 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29.

13.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

14.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC.

Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.

15.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H.

Blood. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.

16.

Differential and limited expression of mutant alleles in multiple myeloma.

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC.

Blood. 2014 Nov 13;124(20):3110-7. doi: 10.1182/blood-2014-04-569327. Epub 2014 Sep 18.

17.

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Pieter Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC.

Leukemia. 2014 Nov;28(11):2229-34. doi: 10.1038/leu.2014.140. Epub 2014 Apr 15.

18.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.

Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.

19.

The shaping and functional consequences of the dosage effect landscape in multiple myeloma.

Samur MK, Shah PK, Wang X, Minvielle S, Magrangeas F, Avet-Loiseau H, Munshi NC, Li C.

BMC Genomics. 2013 Oct 2;14:672. doi: 10.1186/1471-2164-14-672.

20.

Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.

Kang YJ, Zeng W, Song W, Reinhold B, Choi J, Brusic V, Yamashita T, Munshi A, Li C, Minvielle S, Anderson KC, Munshi N, Reinherz EL, Sasada T.

Br J Haematol. 2013 Nov;163(3):343-51. doi: 10.1111/bjh.12544. Epub 2013 Aug 30.

21.

Cereblon expression in multiple myeloma: not ready for prime time.

Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P.

Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. No abstract available.

PMID:
23862718
22.

Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.

Li Y, Wang X, Zheng H, Wang C, Minvielle S, Magrangeas F, Avet-Loiseau H, Shah PK, Zhang Y, Munshi NC, Li C.

PLoS One. 2013;8(3):e58809. doi: 10.1371/journal.pone.0058809. Epub 2013 Mar 15.

23.

Multiple myeloma: so much progress, but so many unsolved questions.

Moreau P, Minvielle S.

Haematologica. 2013 Apr;98(4):487-9. doi: 10.3324/haematol.2013.083592. No abstract available.

24.

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC.

Cancer Cell. 2012 Sep 11;22(3):345-58. doi: 10.1016/j.ccr.2012.08.007.

25.

Minor clone provides a reservoir for relapse in multiple myeloma.

Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, Marit G, Hulin C, Casassus P, Tiab M, Voog E, Randriamalala E, Anderson KC, Moreau P, Munshi NC, Minvielle S.

Leukemia. 2013 Feb;27(2):473-81. doi: 10.1038/leu.2012.226. Epub 2012 Aug 9.

26.

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.

J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726. Epub 2012 Apr 30.

PMID:
22547600
27.

Significant biological role of sp1 transactivation in multiple myeloma.

Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C, Minvielle S, Tai YT, Tassone P, Avet-Loiseau H, Hideshima T, Anderson KC, Munshi NC.

Clin Cancer Res. 2011 Oct 15;17(20):6500-9. doi: 10.1158/1078-0432.CCR-11-1036. Epub 2011 Aug 19.

28.

Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S.

Blood. 2011 Jul 21;118(3):675-8. doi: 10.1182/blood-2011-03-344069. Epub 2011 May 31.

29.

The dChip survival analysis module for microarray data.

Amin SB, Shah PK, Yan A, Adamia S, Minvielle S, Avet-Loiseau H, Munshi NC, Li C.

BMC Bioinformatics. 2011 Mar 9;12:72. doi: 10.1186/1471-2105-12-72.

30.

Pathway-based identification of SNPs predictive of survival.

Pang H, Hauser M, Minvielle S.

Eur J Hum Genet. 2011 Jun;19(6):704-9. doi: 10.1038/ejhg.2011.3. Epub 2011 Feb 2.

31.

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Decaux O, Lamy T, Legros L, Fuzibet JG, Michallet M, Corront B, Lenain P, Hulin C, Mathiot C, Attal M, Facon T, Harousseau JL, Minvielle S, Moreau P; Intergroupe Francophone du Myélome.

Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.

32.

MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.

Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, Minvielle S, Tai YT, Munshi NC, Avet-Loiseau H, Anderson KC, Carrasco DR.

Blood. 2010 Oct 20. doi: 10.1182/blood-2009-11-253294. Epub 2010 Oct 20. Retraction in: Blood. 2011 Jun 30;117(26):7188.

33.

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL.

J Clin Oncol. 2010 Oct 20;28(30):4630-4. doi: 10.1200/JCO.2010.28.3945. Epub 2010 Jul 19.

PMID:
20644101
34.

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H.

Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.

35.

Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.

Decaux O, Clément M, Magrangeas F, Gouraud W, Charbonnel C, Campion L, Loiseau HA, Minvielle S.

Cancer Sci. 2010 Apr;101(4):889-97. doi: 10.1111/j.1349-7006.2009.01467.x. Epub 2009 Dec 11.

36.

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P; IFM and MAG groups.

Leukemia. 2010 Mar;24(3):623-8. doi: 10.1038/leu.2009.273. Epub 2010 Jan 14.

PMID:
20072152
37.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1. Review.

38.

Prognostic significance of copy-number alterations in multiple myeloma.

Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S.

J Clin Oncol. 2009 Sep 20;27(27):4585-90. doi: 10.1200/JCO.2008.20.6136. Epub 2009 Aug 17.

39.

The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.

Romagnoli M, Séveno C, Wuillème-Toumi S, Amiot M, Bataille R, Minvielle S, Barillé-Nion S.

Br J Haematol. 2009 Apr;145(2):180-9. doi: 10.1111/j.1365-2141.2009.07608.x. Epub 2009 Mar 2.

PMID:
19298592
40.

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.

Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.

Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20.

PMID:
19020972
41.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome.

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30.

PMID:
18591550
42.

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.

Campone M, Campion L, Roché H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Jézéquel P.

Breast Cancer Res Treat. 2008 Jun;109(3):491-501. Epub 2007 Jul 21.

PMID:
17659439
43.

[DNA microarrays: technology and new insights in oncology].

Minvielle S.

Rev Med Interne. 2007 Sep;28(9):662-6. Epub 2007 Jun 26. French.

PMID:
17611004
44.

[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].

Decaux O, Lodé L, Minvielle S, Avet-Loiseau H.

Rev Med Interne. 2007 Oct;28(10):677-81. Epub 2007 May 25. Review. French.

PMID:
17559979
45.
46.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C.

Blood. 2007 Apr 15;109(8):3489-95. Epub 2007 Jan 5.

47.

Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.

Ricolleau G, Charbonnel C, Lodé L, Loussouarn D, Joalland MP, Bogumil R, Jourdain S, Minvielle S, Campone M, Déporte-Fety R, Campion L, Jézéquel P.

Proteomics. 2006 Mar;6(6):1963-75.

PMID:
16470659
48.

CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.

Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H.

Leukemia. 2005 Nov;19(11):2021-2. No abstract available.

PMID:
16167057
49.

Genetic heterogeneity in multiple myeloma.

Magrangeas F, Lodé L, Wuilleme S, Minvielle S, Avet-Loiseau H.

Leukemia. 2005 Feb;19(2):191-4. Review.

PMID:
15538406
50.

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.

Wuilleme S, Robillard N, Lodé L, Magrangeas F, Beris H, Harousseau JL, Proffitt J, Minvielle S, Avet-Loiseau H; Intergroupe Francophone de Myélome.

Leukemia. 2005 Feb;19(2):275-8.

PMID:
15538401

Supplemental Content

Loading ...
Support Center